Volume 86 Issue 36 | p. 21 | Concentrates
Issue Date: September 8, 2008

Pfizer, Medivation Sign Alzheimer's Pact

Department: Business

Pfizer has signed an agreement with Medivation, a San Francisco biopharmaceutical firm focused on small molecules, to codevelop and comarket dimebon, a drug for the treatment of Alzheimer's and Huntington's diseases. Under the agreement, Medivation will receive an up-front payment of $225 million, will be eligible to receive payments of up to $500 million upon the attainment of development and regulatory milestones, and could reap undisclosed commercial milestone payments. Dimebon is currently in Phase III clinical trials for Alzheimer's disease.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment